Electronic Supporting Information Materials

Synthesis, crystal structure, cytotoxicity and action mechanism of Rh(III) complex with 8-hydroxy-2-methylquinoline as a ligand

Yun-Liang Zhang^{a,b,†,*}, Qi-Pin Qin^{a,†}, Qian-qian Cao^a, Hong-Hua Han^a, Zhu-Ling Liu^a, Yan-Cheng Liu^a, Hong Liang^a and Zhen-Feng Chen^{a,*}

| Empirical formula | $C_{14}H_{20}C1_2NO_3RhS_2$ | | | |
|---|--|--|--|--|
| Formula weight | 488.26 | | | |
| Temperature/K | 296.15 | | | |
| Crystal system | monoclinic | | | |
| Space group | $P2_1/n$ | | | |
| a/Å | 8.9953(9) | | | |
| b/Å | 15.618(2) | | | |
| c/Å | 13.4715(15) | | | |
| α /° | 90 | | | |
| β∕° | 103.827(12) | | | |
| γ/° | 90 | | | |
| Volume/Å ³ | 1837.7(4) | | | |
| Z | 4 | | | |
| $ ho_{calc}g/cm^3$ | 1.7646 | | | |
| μ / mm^{-1} | 1.459 | | | |
| F (000) | 982.0 | | | |
| Crystal size/mm ³ | $0.22 \times 0.2 \times 0.18$ | | | |
| Radiation | Mo Ka ($\lambda = 0.71073$) | | | |
| 2Θ range for data collection/° | 6.22 to 52.74 | | | |
| Index renges | $-8 \leq h \leq 12$, $-18 \leq k \leq 21$, | | | |
| Index Tanges | $-18 \leqslant 1 \leqslant 17$ | | | |
| Reflections collected | 7465 | | | |
| Independent reflections | 3753 [R_{int} = 0.0903, R_{\text{sigma}} = | | | |
| | 0. 1174] | | | |
| Data/restraints/parameters | 3753/0/212 | | | |
| Goodness-of-fit on F^2 | 1.066 | | | |
| Final R indexes [I>=2 σ (I)] | $R_1 = 0.0956, wR_2 = 0.2539$ | | | |
| Final R indexes [all data] | $R_1 = 0.1281, wR_2 = 0.2872$ | | | |
| Largest diff. peak/hole / e Å ⁻³ | 3. 84/-2. 16 | | | |

 Table S1. Crystal data and structure refinement details for complex 1.

^a $R_1 = \Sigma ||F_0| - |F_c|| / \Sigma |F_0|;$ ^b $wR_2 = [\Sigma w (F_0^2 - F_c^2)^2 / \Sigma w (F_0^2)^2]^{\frac{1}{2}}.$

| Bond lengths (Å) for 1 | | | | | | | | |
|------------------------|------------|--------------|-----------|--------------|-----------|-----------|-------|-----------|
| Rh1-S0aa | 2.295(3) | Rh1-Cl | 2.349(3) | Rh1-S1 | 2.282(3) | Rh1-O1aa | 2.010 | (7) |
| Rh1-N | 2.119(8) | Rh1-Cl8 | 2.359(3) | | | | | |
| Bond angles (°) for 1 | | | | | | | | |
| Cl-Rh1-S0aa | 176.33(10) | S1-Rh1-S0aa | 96.83(10) | S1-Rh1-Cl | 86.83(11) | O1aa-Rh1- | S0aa | 88.6(2) |
| O1aa-Rh1-Cl | 91.3(2) | O1aa-Rh1-S1 | 87.5(2) | N-Rh1-S0aa | 88.2(2) | N-Rh1-Cl | | 88.1(2) |
| N-Rh1-S1 | 168.2(3) | N-Rh1-O1aa | 82.0(3) | Cl8-Rh1-S0aa | 89.30(12) | Cl8-Rh1-C | 1 | 91.21(13) |
| Cl8-Rh1-S1 | 87.00(12) | Cl8-Rh1-O1aa | 173.8(2) | Cl8-Rh1-N | 103.8(3) | C4aa-S0aa | -Rh1 | 115.0(5) |

Table S2 Selected bond lengths (Å) and bond angles (°) for complex 1.

Table S3 Inhibition rates of H-MQ, RhCl₃, complex **1** and cisplatin towards five selected tumor cell lines and one normal liver cell HL-7702 for 48 h.

| Compounds | BEL-7404 | Hep-G2 | NCI-H460 | T-24 | A549 | HL-7702 |
|--------------------------------|------------------|------------|------------|------------------|------------------|------------------|
| H-MQ a | 32.36±1.32 | 37.27±0.64 | 30.98±1.76 | 27.07±0.76 | 31.14±1.39 | 30.47±0.42 |
| 1 a | 60.25±1.81 | 88.49±0.81 | 52.13±0.55 | 61.86±1.25 | 55.09±2.19 | 39.44±0.45 |
| RhCl ₃ ^b | 10.58 ± 1.09 | 18.55±0.56 | 19.11±0.74 | 20.18 ± 1.94 | 14.32 ± 0.83 | 10.85 ± 1.63 |
| Cisplatin ^c | 55.15±1.18 | 60.63±0.99 | 50.88±1.29 | 46.86±1.06 | 52.18±1.47 | 68.95±1.42 |

Results represent mean \pm SD of at least five independent experiments. SD represents the standard deviation. ^a The concentration is 2 ×10⁻⁵ mol/L. ^b The concentration is 1× 10⁻⁴ mol/L. ^c Cisplatin was dissolved at a concentration of 1 mM in 0.154 M NaCl. NA represents no activity.

Table S4. IC_{50}^{a} (μM) values of H-MQ, RhCl₃, complex 1 and cisplatin towards normal liver cell

| Compounds | BEL-7404 | Hep-G2 | NCI-H460 | T-24 | A549 | HL-7702 |
|------------------------|------------------|-----------------|------------------|------------------|------------------|------------------|
| H-MQ | 152.45±1.04 | 137.35±0.58 | 168.92±1.65 | 187.54±0.69 | 107.56±1.03 | 170.65±0.34 |
| 1 | 10.33 ± 1.74 | 6.52 ± 0.83 | 17.86 ± 0.65 | 9.87±1.23 | 15.07 ± 2.33 | 28.74 ± 0.38 |
| RhCl ₃ | >100 | >100 | >100 | >100 | >100 | >100 |
| Cisplatin ^c | 12.41±0.38 | 9.48±0.35 | 18.89 ± 1.02 | 28.86 ± 1.05 | 18.19±1.39 | 15.67±1.27 |

 a IC_{50} values are presented as the mean \pm SD (standard error of the mean) from five independent experiments. b The concentration unit is $\mu M.~^c$ Cisplatin was dissolved at a concentration of 1 mM in 0.154 M NaCl.







Figure S2. ¹H NMR (600 MHz, DMSO-*d*₆) for complex 1.



Figure S3. UV-Vis absorption spectra of complex 1 (4.0×10^{-5} M) in Tris-HCl solution (TBS) in the time course 0, 24 and 48 h, respectively.



Figure S4. UV-Vis absorption spectra of complex $1 (4.0 \times 10^{-5} \text{ M})$ in water in the time course 0, 24 and 48 h, respectively.



Figure S5. The mass spectra of complex **1** in Tris-HCl buffer solution (containing 5% DMSO) for 0 h (top) and 48 h (down), respectively.